Skip to main
ELEV
ELEV logo

Elevation Oncology (ELEV) Stock Forecast & Price Target

Elevation Oncology (ELEV) Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 0%
Buy 33%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Elevation Oncology Inc is noted for its promising candidate EO-3021, an antibody-drug conjugate designed for treating a variety of solid tumors, showing a noteworthy objective response rate of 43% in a selected patient population. The anticipated upcoming data releases, specifically additional monotherapy results in Q2 2025 and combination therapy results in late 2025 to early 2026, are expected to bolster investor confidence, potentially facilitating access to further capital. Moreover, the innovative combination therapy strategies involving EO-3021 with other agents like dostarlimab and ramucirumab may enhance treatment profiles, addressing unmet medical needs in several cancer types, which collectively contribute to a favorable outlook for the company's stock.

Bears say

Elevation Oncology faces significant financial challenges that contribute to a negative outlook on its stock. The company's inability to access capital could disrupt its operations, impacting the timeline for achieving profitability and cash flow generation. Furthermore, the recent Phase 1 trial results for EO-3021 demonstrated efficacy primarily in a subset of patients, raising concerns about the broader market potential and contributing to unfavorable perceptions among investors, especially in light of the lack of revenue reported in 4Q24 and a net loss that was better than estimates but still indicative of ongoing financial strain.

Elevation Oncology (ELEV) has been analyzed by 9 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 33% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Elevation Oncology and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Elevation Oncology (ELEV) Forecast

Analysts have given Elevation Oncology (ELEV) a Hold based on their latest research and market trends.

According to 9 analysts, Elevation Oncology (ELEV) has a Hold consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Elevation Oncology (ELEV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.